CASPIAN Proves Too Choppy For AZ Imfinzi/Tremelimumab Combo
But Imfinzi Benefit Reinforced For Small Cell Lung Cancer
Executive Summary
Another day and another fail for AstraZeneca's combination of Imfinzi and tremelimumab, this time for extensive-stage small-cell lung cancer.
You may also be interested in...
AstraZeneca's Imfinzi/Tremelimumab Combo Conquers HIMALAYA
After the combination's success in the non-small cell lung cancer POSEIDON study, AstraZeneca's Imfinzi and tremelimumab could now be on the way to approval as a first-line treatment for hepatocellular carcinoma.
At Last, AZ’s Imfinzi/Tremelimumab Cancer Combo Shows Survival Benefit
After five years of failure in NSCLC trials, AstraZeneca’s immunotherapy combo shows survival benefits in POSEIDON.
Roche's Tecentriq Notches Approval For First-Line NSCLC Monotherapy
The company is getting more attention these days for its TIGIT inhibitor tiragolumab in combination with Tecentriq for 1L NSCLC, but a new 1L monotherapy indication for Tecentriq helps it compete against Keytruda.